Data elements for reporting serious adverse events occurring in a clinical trial or bio availability or bioequivalence study

  1. Patient Details:
    Initials and other relevant identifier (hospital or out-patient department (OPD) record number etc.)*
    Gender
    Age or date of birth
    Weight
    Height
  2. Suspected Drug(s):
    • Generic name of the drug*
    • Indication(s) for which suspect drug was prescribed or tested.
    • Dosage form and strength.
    • Daily dose and regimen (specify units – e.g., mg, ml, mg /kg).
    • Route of administration.
    • Starting date and time of day.
    • Stopping date and time, or duration of treatment
  3. Other Treatment(s):
    • Provide the same information for concomitant drugs (including non-prescription or Over the Counter OTC drugs) and non-drug therapies, as for the suspected drug(s).
  4. Details of Serious Adverse Event:
    • Full description of the event including body site and severity, as well as the criterion (or criteria) for considering the report as serious. In addition to a description of the reported signs and symptoms, whenever possible, describe a specific diagnosis for the event*
    • Start date (and time) of onset of event.
    • Stop date (and time) or duration of event.
    • Dechallenge and rechallenge information.
    • Setting (e.g., hospital, out-patient clinic, home, nursing home).
  5. Outcome
    • Information on recovery and any sequelae; results of specific tests or treatment that may have been conducted.
    • For a fatal outcome, cause of death and a comment on its possible relationship to the suspected event; Any post-mortem findings.
    • Other information: anything relevant to facilitate assessment of the case, such as medical history including allergy, drug or alcohol abuse; family history; findings from special investigations etc.
  6. Details about the Investigator*
    • Name and Address
    • Telephone number Profession (specialty)
    • Date of reporting the event to Central Licencing Authority:
    • Date of reporting the event to ethics committee overseeing the site:
    • Signature of the Investigator or Sponsor
    • Note: Information marked * must be provided.

Discover more from सुदर्शन

Subscribe to get the latest posts sent to your email.

error: Content is protected !!